EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

A nationwide phase II study of delayed local treatment for children with high‐risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN‐H‐11

Akihiro Yoneda iD, Hiroyuki Shichino, Tomoro Hishiki iD, Kimikazu Matsumoto iD, Miki Ohira iD, Takehiko Kamijo iD, Tatsuo Kuroda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai und 8 weitere

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30976 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Akihiro Yoneda und 19 weiteren Autor:innen. Beteiligte Einrichtung: The Japan Children's Cancer Group (JCCG) Neuroblastoma Committee (JNBSG), Nagoya, Japan. Hauptthemen laut MEDLINE: Neuroblastoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Developement.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Survival rates of patients with high‐risk neuroblastoma are unacceptable. A time‐intensified treatment strategy with delayed local treatment to control systemic diseases has been developed in Japan. We conducted a nationwide, prospective, single‐arm clinical trial with delayed local treatment. This study evaluated the safety and efficacy of delayed surgery to increase treatment intensity. Patients and methods Seventy‐five patients with high‐risk neuroblastoma were enrolled in this study between May 2011 and September 2015. Delayed local treatment consisted of five courses of induction chemotherapy (cisplatin, pirarubicin, vincristine, and cyclophosphamide) and myeloablative high‐dose chemotherapy (melphalan, etoposide, and carboplatin), followed by local tumor extirpation with surgery and irradiation. The primary endpoint was progression‐free survival (PFS). The secondary endpoints were overall survival (OS), response rate, adverse events, and surgical complications.

Results

Seventy‐five patients were enrolled, and 64 were evaluable (stage 3, n = 8; stage 4, n = 56). The estimated 3‐year PFS and OS rates (95% confidence interval [CI]) were 44.4% [31.8%–56.3%] and 80.7% [68.5%–88.5%], resspectively. The response rate of INRC after completion of the treatment protocol was 66% (42/64; 95% CI: 53%–77%; 23 CR [complete response], 10 VGPR [very good partial response], and nine PR [partial response]). None of the patients died during the protocol treatment or within 30 days of completion. Grade 4 adverse effects, excluding hematological adverse effects, occurred in 48% of patients [31/64; 95% CI: 36%–61%]. Major Surgical complications were observed in 25% of patients [13/51; 95% CI: 14%–40%].

Conclusion

This study indicates that delayed local treatment is feasible and shows promising efficacy, suggesting that this treatment should be considered further in a comparative study of high‐risk neuroblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleChild, PreschoolInfantChildJapanProspective StudiesSurvival RateAdolescentInduction ChemotherapyEtoposideFollow-Up StudiesVincristineCombined Modality TherapyCyclophosphamidePrognosisDoxorubicinMelphalanCisplatin

Stichwörter der Autor:innen

clinical trialdelayed local treatmenthigh riskmultidisciplinary treatmentneuroblastoma

Substanzen

EtoposideVincristineCyclophosphamideDoxorubicinpirarubicinMelphalanCisplatin

Autor:innen und Institutionen

  • The Japan Children's Cancer Group (JCCG) Neuroblastoma Committee (JNBSG), Nagoya, Japan.
  • Surgery, Surgical Oncology, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
  • Pediatric Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan.
  • Pediatric Surgery, Chiba University, Chiba, Japan.
  • Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.

ORCID-Profile: Akihiro Yoneda, Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo

Förderung

  • Japan Agency for Medical Research and Developement

Zitieren

APA

Yoneda, A., Shichino, H., Hishiki, T., Matsumoto, K., Ohira, M., Kamijo, T., Kuroda, T., Soejima, T., Nakazawa, A., Takimoto, T., Yokota, I., Teramukai, S., Takahashi, H., Fukushima, T., Hara, J., Kaneko, M., Ikeda, H., Tajiri, T., Mugishima, H., & Nakagawara, A. (2024). A nationwide phase II study of delayed local treatment for children with high‐risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN‐H‐11. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30976

Vancouver

Yoneda A, Shichino H, Hishiki T, Matsumoto K, Ohira M, Kamijo T, et al. A nationwide phase II study of delayed local treatment for children with high‐risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN‐H‐11. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30976

BibTeX
@article{Yoneda2024,
  author = {Yoneda, Akihiro and Shichino, Hiroyuki and Hishiki, Tomoro and Matsumoto, Kimikazu and Ohira, Miki and Kamijo, Takehiko and Kuroda, Tatsuo and Soejima, Toshinori and Nakazawa, Atsuko and Takimoto, Tetsuya and Yokota, Isao and Teramukai, Satoshi and Takahashi, Hideto and Fukushima, Takashi and Hara, Junichi and Kaneko, Michio and Ikeda, Hitoshi and Tajiri, Tatsuro and Mugishima, Hideo and Nakagawara, Akira},
  title = {A nationwide phase II study of delayed local treatment for children with high‐risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN‐H‐11},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30976}
}
Kostenlos starten →